[
  {
    "ts": null,
    "headline": "S&P 500 & Nasdaq Notch New All-Time Closing Highs",
    "summary": "Markets lost a bit of steam mid-session this Monday, but a late surge into the close brought the S&P 500 and the Nasdaq indexes to new record closing highs.",
    "url": "https://finnhub.io/api/news?id=31a3a9c01f70d195c671774043f9f79dd1f74c3d14acecd56ba613bffec26833",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753740060,
      "headline": "S&P 500 & Nasdaq Notch New All-Time Closing Highs",
      "id": 136113393,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Markets lost a bit of steam mid-session this Monday, but a late surge into the close brought the S&P 500 and the Nasdaq indexes to new record closing highs.",
      "url": "https://finnhub.io/api/news?id=31a3a9c01f70d195c671774043f9f79dd1f74c3d14acecd56ba613bffec26833"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reports Earnings Tuesday. Key Products Are Under Threat.",
    "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
    "url": "https://finnhub.io/api/news?id=046582f661432117a69e8d4010dc8f1c66c08c443e36c39e3678339969eeb789",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753734600,
      "headline": "Merck Reports Earnings Tuesday. Key Products Are Under Threat.",
      "id": 136113451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
      "url": "https://finnhub.io/api/news?id=046582f661432117a69e8d4010dc8f1c66c08c443e36c39e3678339969eeb789"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712880,
      "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136108008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings",
    "summary": "Merck & Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29. Analysts expect the health care company to report quarterly earnings at $2.03 per share, down from $2.28 per share in the year-ago period. Merck projects to report quarterly revenue at $15.87 billion, compared to $16.11 billion a year earlier, according to data from Benzinga Pro. With the recent buzz around Merck, some investors may be eyeing potential gains from the com",
    "url": "https://finnhub.io/api/news?id=ff833890cd2fec19d3dc9153c1cf4d2a467134f7cd7bd608be7f1f59b3714dfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753704743,
      "headline": "How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings",
      "id": 136108172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) will release earnings results for the second quarter before the opening bell on Tuesday, July 29. Analysts expect the health care company to report quarterly earnings at $2.03 per share, down from $2.28 per share in the year-ago period. Merck projects to report quarterly revenue at $15.87 billion, compared to $16.11 billion a year earlier, according to data from Benzinga Pro. With the recent buzz around Merck, some investors may be eyeing potential gains from the com",
      "url": "https://finnhub.io/api/news?id=ff833890cd2fec19d3dc9153c1cf4d2a467134f7cd7bd608be7f1f59b3714dfb"
    }
  },
  {
    "ts": null,
    "headline": "Trade Outlook Lifts Wall Street Pre-Bell; Asia Choppy, Europe Up",
    "summary": "Wall Street futures pointed to fresh all-time highs pre-bell Monday as traders weighed media reports",
    "url": "https://finnhub.io/api/news?id=beef7367a3012c30a1c89c7c047540643bdcbd5bef8a56e6c45ef345d6bdf53c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753702065,
      "headline": "Trade Outlook Lifts Wall Street Pre-Bell; Asia Choppy, Europe Up",
      "id": 136107950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wall Street futures pointed to fresh all-time highs pre-bell Monday as traders weighed media reports",
      "url": "https://finnhub.io/api/news?id=beef7367a3012c30a1c89c7c047540643bdcbd5bef8a56e6c45ef345d6bdf53c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Announces Data to be Presented at ESMO Congress 2025",
    "summary": "CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) ...",
    "url": "https://finnhub.io/api/news?id=0f8a50feb60370d0da841da5fd574161d2a37e48e93cec04b9b823d071ffed6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753700400,
      "headline": "Moderna Announces Data to be Presented at ESMO Congress 2025",
      "id": 136108174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) ...",
      "url": "https://finnhub.io/api/news?id=0f8a50feb60370d0da841da5fd574161d2a37e48e93cec04b9b823d071ffed6a"
    }
  },
  {
    "ts": null,
    "headline": "3 Surprisingly Underrated Stocks to Buy Right Now",
    "summary": "These big pharma stocks arguably aren't receiving the respect they deserve.",
    "url": "https://finnhub.io/api/news?id=2c18cb1b8ebe9da6cde6ba07872a248209a27dcaf7dd2002bf551202ec5842f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753699320,
      "headline": "3 Surprisingly Underrated Stocks to Buy Right Now",
      "id": 136108175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These big pharma stocks arguably aren't receiving the respect they deserve.",
      "url": "https://finnhub.io/api/news?id=2c18cb1b8ebe9da6cde6ba07872a248209a27dcaf7dd2002bf551202ec5842f2"
    }
  },
  {
    "ts": null,
    "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
    "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
    "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753689660,
      "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
      "id": 136107937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
      "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) on July 21, bringing the price target down to $92 from $115. The analyst told investors that Merck & Co., Inc.’s (NYSE:MRK) […]",
    "url": "https://finnhub.io/api/news?id=28a7e60991ae8d654e3193c73c399004a53f391f2af3dc8c2a27f72ea60d57d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682888,
      "headline": "Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115",
      "id": 136108177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) on July 21, bringing the price target down to $92 from $115. The analyst told investors that Merck & Co., Inc.’s (NYSE:MRK) […]",
      "url": "https://finnhub.io/api/news?id=28a7e60991ae8d654e3193c73c399004a53f391f2af3dc8c2a27f72ea60d57d7"
    }
  },
  {
    "ts": null,
    "headline": "What To Expect From Merck’s (MRK) Q2 Earnings",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=749214a8999996edc03d0b131b236f742eab3307d8dd1d9a771f2dc04efa7da2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753672066,
      "headline": "What To Expect From Merck’s (MRK) Q2 Earnings",
      "id": 136108178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=749214a8999996edc03d0b131b236f742eab3307d8dd1d9a771f2dc04efa7da2"
    }
  }
]